Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Onondaga
    4. ›
  4. 13084
    5. ›
  5. ICHOR LIFE SCIENCES, INC.

ICHOR LIFE SCIENCES, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: ICHOR LIFE SCIENCES, INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 03 May 2013 (12 years ago)
Entity Number: 4398247
ZIP code: 13084
County: Onondaga
Place of Formation: New York
Address: 2561 US Route 11, LA FAYETTE, NY, United States, 13084
Principal Address: 2561 US ROUTE 11, LA FAYETTE, NY, United States, 13084

Shares Details

Shares issued 2000000

Share Par Value 0.001

Type PAR VALUE

Chief Executive Officer

Name Role Address
KELSEY MOODY Chief Executive Officer 2561 US ROUTE 11, LA FAYETTE, NY, United States, 13084

DOS Process Agent

Name Role Address
ICHOR LIFE SCIENCES, INC. DOS Process Agent 2561 US Route 11, LA FAYETTE, NY, United States, 13084

Agent

Name Role Address
KELSEY MOODY Agent 2521 US ROUTE 11, LAFAYETTE, NY, 13084

U.S. Small Business Administration Profile

Website:
www.ichorlifesciences.com
Phone Number:
315-380-4700
E-mail Address:
awolfe@ichorlifesciences.com
Contact Person:
AARON WOLFE
User ID:
P2659730
Trade Name:
ICHOR LIFE SCIENCES

Unique Entity ID

Unique Entity ID:
TB9KBM6FP991
CAGE Code:
7ZLW0
UEI Expiration Date:
2025-10-07

Business Information

Doing Business As:
ICHOR LIFE SCIENCES
URL:
www.ichorlifesciences.com
Activation Date:
2024-10-09
Initial Registration Date:
2017-10-31

Commercial and government entity program

CAGE number:
7ZLW0
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-10-09
CAGE Expiration:
2029-10-09
SAM Expiration:
2025-10-07

Contact Information

POC:
AARON WOLFE
Corporate URL:
www.ichorlifesciences.com

History

Start date End date Type Value
2025-05-02 2025-05-02 Address 2521 US ROUTE 11, LA FAYETTE, NY, 13084, USA (Type of address: Chief Executive Officer)
2025-05-02 2025-05-02 Address 2561 US ROUTE 11, LA FAYETTE, NY, 13084, USA (Type of address: Chief Executive Officer)
2024-03-12 2025-05-02 Shares Share type: PAR VALUE, Number of shares: 2000000, Par value: 0.001
2024-02-27 2024-03-12 Shares Share type: PAR VALUE, Number of shares: 2000000, Par value: 0.001
2024-02-22 2024-02-22 Address 2561 US ROUTE 11, LA FAYETTE, NY, 13084, USA (Type of address: Chief Executive Officer)

Filings

Filing Number Date Filed Type Effective Date
250502003849 2025-05-02 BIENNIAL STATEMENT 2025-05-02
240222001917 2024-02-22 BIENNIAL STATEMENT 2024-02-22
210914001920 2021-09-14 CERTIFICATE OF AMENDMENT 2021-09-14
210518060502 2021-05-18 BIENNIAL STATEMENT 2021-05-01
200213000723 2020-02-13 CERTIFICATE OF AMENDMENT 2020-02-13

USAspending Awards / Financial Assistance

Date:
2024-03-29
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
AWARDTYPE: GUARANTEED/INSURED LOANS ACTIVITIES TO BE PERFORMED: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES WHICH ARE UNABLE TO OBTAIN FINANCING IN THE PRIVATE CREDIT MARKETPLACE BUT CAN DEMONSTRATE AN ABILITY TO REPAY LOANS IF GRANTED, IN A TIMELY MANNER. THE SBA GUARANTEES 7(A) PROGRAM LOANS THROUGH VARIOUS LOAN PROCESSING METHODS INCLUDING: (1) STANDARD 7(A) LOANS; (2) 7(A) SMALL LOANS; (3) SBAEXPRESS LOANS; (4) CAPLINE LOANS; (5) THE QUALIFIED EMPLOYEE TRUSTS (ESOP); (6) EXPORT EXPRESS; (7)EXPORT WORKING CAPITAL PROGRAM (EWCP); (8) INTERNATIONAL TRADE, AND (9) PILOT (TEMPORARY) PROGRAMS. DELIVERABLES: LOAN GUARANTEES EXPECTED OUTCOMES: TO PROVIDE GUARANTEED LOANS FROM LENDERS TO ELIGIBLE FOR PROFIT SMALL BUSINESSES AND, IN CERTAIN CIRCUMSTANCES, TO QUALIFIED EMPLOYEE TRUSTS (ESOPS). INTENDED BENEFICIARIES: SMALL BUSINESSES SUBRECIPIENT ACTIVITIES: NA
Obligated Amount:
0.00
Face Value Of Loan:
1712900.00
Total Face Value Of Loan:
1712900.00
Date:
2022-08-18
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF A NOVEL THERAPY FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION - PROJECT SUMMARY AGE-RELATED MACULAR DEGENERATION (AMD), A LEADING CAUSE OF BLINDNESS, AFFECTS 18 MILLION PEOPLE IN THE US. THE “WET” FORM OF AMD IS CHARACTERIZED BY PATHOLOGICAL NEOVASCULARIZATION AND MACULAR BLEEDING WHILE THE “DRY” AMD FORM IS CHARACTERIZED BY NO VISIBLE VASCULARIZATION. STRATEGIES TO TREAT WET AMD, INCLUDING ANTIOXIDANT THERAPY, PROPHYLACTIC LASER THERAPY, SURGICAL INTERVENTION, AND ANTI-NEOVASCULAR AGENTS, ARE PRIMARILY PALLIATIVE AND EXTEND THE TIME A PATIENT RETAINS FUNCTIONAL VISION. ALL CURRENT FDA-APPROVED AMD TREATMENTS FOCUS ON SLOWING THE PROGRESSION OF THE WET STAGE OF THE DISEASE BY INHIBITING THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) PATHWAY. HOWEVER, WET AMD FORMS ON A BACKGROUND OF DRY AMD, WHICH ALWAYS DEVELOPS BEFORE NEOVASCULARIZATION. THE CURRENT STANDARD OF CARE FOR DRY AMD REDUCES THE RISK OF PROGRESSION FROM INTERMEDIATE TO ADVANCED AMD BY ~25% BUT DOES NOT PREVENT ONSET OF AMD. NO FDA-APPROVED DRUG TREATMENTS EXIST FOR DRY AMD. A HALLMARK OF AMD IS THE ACCUMULATION OF BISRETINOIDS IN THE LYSOSOMES OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS. THE MOST COMMON BISRETINOID, N-RETINYL-N-RETINYLIDENE ETHANOLAMINE (A2E), DEVELOPS AS A BYPRODUCT OF THE VISUAL CYCLE. A2E IS CYTOTOXIC IN CELL CULTURE MODELS AND APPEARS TO BE A CAUSATIVE FACTOR IN THE FORMATION OF LIPOFUSCIN. LIPOFUSCIN BISRETINOIDS ARE ROBUST AND GENERALLY NOT DEGRADED BY LYSOSOMAL ENZYMES. OVER TIME, THEY BUILD UP AND CONTRIBUTE TO LYSOSOMAL DYSFUNCTION AND PROGRESSION OF AMD. STRATEGIES TO BREAK DOWN ACCUMULATED LIPOFUSCIN HAVE THE POTENTIAL TO DELAY OR EVEN REVERSE DRY AMD. ICHOR THERAPEUTICS IS DEVELOPING A NOVEL ENZYME THERAPY, WHICH WE INTEND TO BRING TO MARKET AS THE FIRST FDA-APPROVED DRY AMD DRUG. BASED ON OUR BREAKTHROUGH DISCOVERY THAT RECOMBINANT MANGANESE PEROXIDASE DEGRADES A2E IN VITRO AND IN A MOUSE MODEL OF AMD, WE ARE EXPANDING THIS WORK TO IDENTIFY PEROXIDASES SUITABLE FOR CLINICAL DEVELOPMENT. KEY CHARACTERISTICS ARE HIGH ACTIVITY AT LYSOSOMAL PH, INCREASED POTENCY FOR DEGRADATION OF A2E AND RELATED RETINOIDS, AMENABLE TO ENGINEERING FOR CELL AND LYSOSOMAL DELIVERY, AND SUITABLE FOR LARGE SCALE PRODUCTION IN BACTERIAL SYSTEMS. THE SCOPE OF OUR PHASE I EFFORT INCLUDES: 1) GENERATING AND CHARACTERIZING PEROXIDASES FROM DIFFERENT MICROBIAL SOURCES, 2) CONJUGATING OPTIMALLY PERFORMING PEROXIDASES TO CELL PENETRATING PEPTIDES TO OPTIMIZE TARGETING TO RPE CELLS AND SUBCELLULAR TARGETING TO LYSOSOMES, AND 3) EVALUATING OCULAR TOLERANCE AND BIOLOGICAL ACTIVITY IN AN ANIMAL MODEL OF AMD. SUCCESSFUL COMPLETION OF OUR OBJECTIVES WILL JUSTIFY IND-ENABLING STUDIES OF OUR LEAD ENZYME IN PHASE II.
Obligated Amount:
299703.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Jobs Reported:
27
Initial Approval Amount:
$430,365
Date Approved:
2020-04-27
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$430,365
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
$435,953.85
Servicing Lender:
Manufacturers and Traders Trust Company
Use of Proceeds:
Payroll: $392,320
Utilities: $10,094
Mortgage Interest: $10,123
Rent: $2,500
Healthcare: $11828
Debt Interest: $3,500
Jobs Reported:
33
Initial Approval Amount:
$423,100
Date Approved:
2021-03-12
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$423,100
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
$428,594.5
Servicing Lender:
Manufacturers and Traders Trust Company
Use of Proceeds:
Payroll: $423,096
Utilities: $1

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

KELSEY MOODY

KELSEY MOODY & ASSOCIATES, LLC WOODLAND BIOSCIENCES, INC. ICARIA LIFE SCIENCES, INC. AUCTUS BIOLOGICS, INC. ICHOR RESEARCH IV, INC. ICHOR LABORATORY SOLUTIONS, INC. MOODY VENTURES, INC. FOXBIO INC

Related by address

No related companies by address

Date of last update: 26 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated